28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
We found that AD cases with comorbid LATE-NC, AD(LATE-NC+), have increased burdens of pretangles and/or NFTs as well as increased brain levels of p-tau199, compared to AD(LATE-NC-) cases and controls. 5 key findings →
Participants: 98 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Concomitant LATE-NC and vascular pathology were equally common, and cognition was equally impaired, in PART (Mini-Mental State Examination [MMSE] = 24.8 ± 6.9) and ADNC (MMSE = 24.2 ± 6.0). 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared to those without LATE-NC or ADNC, those with pure LATE-NC had a faster decline in global cognition (p = 0.025) and episodic memory (p = 0.002); however, compared to persons with pure ADNC, those with pure LATE-NC showed a slower decline. 5 key findings →
Participants: 378 Evidence: low
Full summary, score breakdown and related studies → Original source
Elderly human brains are vulnerable to multiple proteinopathies, although each protein has a different transmission pathway. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Oldest-old care recipients were more impaired in cognitive function and instrumental ADL; there was no difference in behavior and basic ADL. 5 key findings →
Participants: 458 Evidence: low
Full summary, score breakdown and related studies → Original source
The study results identified that dementia-related factors were the most significant factors, representing 25.6% of caregiver burden and were followed by caregiving-related factors explaining caregiver burden significantly. 3 key findings →
Participants: 1,133 Evidence: low
Full summary, score breakdown and related studies → Original source
In total, 208 (response rate2010: 51.05%, response rate2015=60.65%) bereaved relatives responded to the questionnaire. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Forty-three percent of the residents were not able to perform the balance test in SPPB. 5 key findings →
Participants: 696 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 927 hospitalized patients with dementia, 17% received IPCC (N = 157). 5 key findings →
Participants: 157 Evidence: low
Full summary, score breakdown and related studies → Original source
Planning for future medical treatment, and care, referred to as advance care planning (ACP), has evolved to a focus on conversations that explore values and preferences in a broad sense. 1 key finding →
Participants: 131 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 54.4% of the residents with dementia had been provided with information about their state of health, compared to 92.5% of the residents without dementia (p < 0.01); family members exhibited no differences regarding information (p = 0.658), regardless of whether the resident was cognitively impaired. 4 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
Black and Hispanic older adults have significantly lower rates of ACP relative to Whites. 5 key findings →
Participants: 8,912 Evidence: low
Full summary, score breakdown and related studies → Original source
Higher NIH Toolbox Friendship scores predicted less episodic memory decline. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
When considering race/ethnicity, the presence of more vascular comorbidities drove greater vulnerability. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the included 3 515 329 Medicare fee-for-service decedents, when adjusted for age and sex, the percentage of older decedents with an ADRD diagnosis increased from 34.7% in 2004 to 47.2% in 2017. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The incremental cost of the lecanemab group compared to the aducanumab group was $30,018.97, with an increase in quality-adjusted life-years (QALYs) of 0.25, resulting in an ICER of $121,678.49 per QALY gained. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
In total, 1006 elderly were interviewed, with a 66.18% response rate. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Research on music therapy for older adults is a rapidly expanding and involves strong global collaboration. 2 key findings →
Participants: 5,253 Evidence: low
Full summary, score breakdown and related studies → Original source
This study demonstrated that APOE4 carrier status was associated with lower MoCA-INA scores in this small VaD cohort. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Alzheimer’s Disease Sequencing Project (ADSP) performed whole genome sequencing (WGS) of 584 subjects from 111 multiplex families at three sequencing centers. 1 key finding →
Participants: 584 Evidence: low
Full summary, score breakdown and related studies → Original source
Variation in human lifespan is 20 to 30% heritable in twins but few genetic variants have been identified. 3 key findings →
Participants: 75,244 Evidence: low
Full summary, score breakdown and related studies → Original source
See Vandenberghe and Schaeverbeke (doi:10.1093/awx065) for a scientific commentary on this article. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD). 2 key findings →
Design: clinical trial Participants: 500 Evidence: high
Full summary, score breakdown and related studies → Original source
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. 4 key findings →
Design: clinical trial Participants: 684 Evidence: high
Full summary, score breakdown and related studies → Original source
Subjects taking antihypertensive medication (n = 651, 83.9% of whom took diuretics) had a lower prevalence of dementia than those not taking antihypertensive medication (P<.001). 5 key findings →
Participants: 651 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →